Tetra Bio-Pharma received orphan drug designation from the FDA for the cannabinoid drug PPP003 to prevent proliferative vitreoretinopathy, according to a press release.
The standard of care of repeat surgery “does not address the inflammatory basis of the condition,” which may lead to a higher risk for endophthalmitis, the release said.
“Our research in an experimental model of PVR has demonstrated that the synthetic cannabinoid, PPP003, can prevent this condition through activation of the type 2 cannabinoid receptor. If Tetra’s clinical trial can successfully
Uncategorized